American Century Companies Inc. Has $450.52 Million Stock Holdings in IDEXX Laboratories, Inc. $IDXX

American Century Companies Inc. lowered its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 17.3% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 705,158 shares of the company’s stock after selling 148,003 shares during the quarter. American Century Companies Inc. owned 0.88% of IDEXX Laboratories worth $450,518,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Huntington National Bank raised its holdings in IDEXX Laboratories by 3.0% in the 3rd quarter. Huntington National Bank now owns 3,760 shares of the company’s stock valued at $2,402,000 after acquiring an additional 109 shares during the period. Handelsbanken Fonder AB increased its stake in shares of IDEXX Laboratories by 0.3% during the third quarter. Handelsbanken Fonder AB now owns 33,595 shares of the company’s stock worth $21,464,000 after purchasing an additional 116 shares during the period. Generali Investments Management Co LLC boosted its stake in IDEXX Laboratories by 135.3% in the 3rd quarter. Generali Investments Management Co LLC now owns 847 shares of the company’s stock valued at $541,000 after purchasing an additional 487 shares during the period. Andra AP fonden grew its holdings in IDEXX Laboratories by 533.1% in the 3rd quarter. Andra AP fonden now owns 29,900 shares of the company’s stock valued at $19,103,000 after buying an additional 25,177 shares in the last quarter. Finally, TIAA Trust National Association increased its position in IDEXX Laboratories by 4.1% during the 3rd quarter. TIAA Trust National Association now owns 2,238 shares of the company’s stock worth $1,430,000 after buying an additional 89 shares during the period. 87.84% of the stock is owned by institutional investors.

Analysts Set New Price Targets

IDXX has been the subject of a number of analyst reports. Morgan Stanley raised their price objective on IDEXX Laboratories from $765.00 to $805.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 4th. Jefferies Financial Group restated a “buy” rating and issued a $830.00 target price on shares of IDEXX Laboratories in a research note on Tuesday, November 4th. JPMorgan Chase & Co. upped their price target on IDEXX Laboratories from $675.00 to $775.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 4th. Weiss Ratings lowered shares of IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Thursday, January 29th. Finally, Leerink Partners set a $785.00 target price on IDEXX Laboratories in a research report on Monday, November 3rd. Seven equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $783.33.

Insider Buying and Selling

In other IDEXX Laboratories news, EVP Michael G. Erickson sold 5,371 shares of IDEXX Laboratories stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $627.38, for a total value of $3,369,657.98. Following the completion of the sale, the executive vice president owned 12,693 shares of the company’s stock, valued at approximately $7,963,334.34. The trade was a 29.73% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Nimrata Hunt sold 2,693 shares of IDEXX Laboratories stock in a transaction on Thursday, February 26th. The stock was sold at an average price of $661.54, for a total value of $1,781,527.22. Following the completion of the sale, the executive vice president directly owned 19,899 shares of the company’s stock, valued at $13,163,984.46. The trade was a 11.92% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 20,873 shares of company stock worth $13,408,523 in the last 90 days. 0.98% of the stock is owned by company insiders.

IDEXX Laboratories Price Performance

Shares of IDEXX Laboratories stock opened at $656.73 on Friday. The firm has a market capitalization of $52.29 billion, a PE ratio of 50.25, a price-to-earnings-growth ratio of 4.01 and a beta of 1.67. The company has a current ratio of 1.23, a quick ratio of 0.90 and a debt-to-equity ratio of 0.23. IDEXX Laboratories, Inc. has a 12 month low of $356.14 and a 12 month high of $769.98. The business’s 50-day moving average price is $672.95 and its 200-day moving average price is $668.97.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings results on Monday, February 2nd. The company reported $2.92 EPS for the quarter, missing analysts’ consensus estimates of $2.93 by ($0.01). The firm had revenue of $1.09 billion for the quarter, compared to the consensus estimate of $1.07 billion. IDEXX Laboratories had a net margin of 24.62% and a return on equity of 69.78%. The company’s quarterly revenue was up 14.3% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.53 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. Sell-side analysts forecast that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.